The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria

Newton, Paul N.; Barnes, Karen I.; Smith, Peter J.; Evans, Alicia C.; Wirongrong Chierakul; Ruangveerayuth, Ronatrai; White, Nicholas J.
December 2006
European Journal of Clinical Pharmacology;Dec2006, Vol. 62 Issue 12, p1003
Academic Journal
Intravenous artesunate is commonly used in the emergency treatment of patients with severe falciparum malaria in Asia. The choice of doses used has been empirical. To inform dosage recommendations we assessed the pharmacokinetics of intravenous artesunate after the first dose. As part of a clinical trial of artesunate in adults with severe falciparum malaria in western Thailand, we assayed plasma concentrations of artesunate and the principal biologically active metabolite dihydroartemisinin (DHA) in 17 patients given an initial dose of 2.4 mg/kg body weight of intravenous artesunate. Drug levels were measured using high performance liquid chromatography with mass spectroscopy-electrospray ionisation detection. Median (range) observed DHA Cmax was 2128 (513–5789) nmol/L, elimination half-life was 0.34 (0.14–0.87) h, and the time to the last detectable DHA was 2 h. The large inter-individual variability (10 fold) in DHA Cmax and AUC in patients with potentially lethal, severe malaria, suggests that 2.4 mg/kg should be the minimum daily dose in severe malaria.


Related Articles

  • Effect of High-Dose or Split-Dose Artesunate on Parasite Clearance in Artemisinin-Resistant Falciparum Malaria. Das, Debashish; Tripura, Rupam; Phyo, Aung Pyae; Lwin, Khin Maung; Tarning, Joel; Lee, Sue J.; Hanpithakpong, Warunee; Stepniewska, Kasia; Menard, Didier; Ringwald, Pascal; Silamut, Kamolrat; Imwong, Mallika; Chotivanich, Kesinee; Yi, Poravuth; Day, Nicholas P. J.; Lindegardh, Niklas; Socheat, Duong; Nguon, Chea; White, Nicholas J.; Nosten, François // Clinical Infectious Diseases;Mar2013, Vol. 56 Issue 5, pe48 

    New treatment strategies are needed for artemisinin-resistant falciparum malaria. This randomized trial shows that neither increasing nor splitting the standard once-daily artesunate dose reverses the markedly reduced parasite clearance rate in patients with artemisinin-resistant falciparum...

  • Editorial Commentary: Effectiveness or Efficacy: Which Study to Evaluate Antibiotics in Neonates? Jacqz-Aigrain, Evelyne // Clinical Infectious Diseases;Dec2012, Vol. 55 Issue 11, p1503 

    The author discusses aspects of a study on the safety and effectiveness of the anti-infective agent meropenem in newborn infants. She mentions the basis of the drug's dosage regimen on pharmacokinetic (PK) data which was adapted to bodyweight and gestational and postnatal ages. She also notes...

  • PIII-74. Jang, S.; Han, T.; Park, K. // Clinical Pharmacology & Therapeutics;Feb2006, Vol. 79 Issue 2, pP78 

    Background: To analyze propofol pharmacokinetics in Koreans and to examine the covariate effects.Methods: Propofol pharmacokinetics was studied in 19 healthy Koreans (21-54 years, 44-86 kg, ASA(American Society of Anesthesiologists) class I or II) who received a single intravenous dose of 2mg/kg...

  • Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. Brendel, Erich; Ludwig, Matthias; Lathia, Chetan; Robert, Caroline; Ropert, Stanislas; Soria, Jean-Charles; Armand, Jean-Pierre // Cancer Chemotherapy & Pharmacology;Jul2011, Vol. 68 Issue 1, p53 

    Purpose: Sorafenib, a multikinase inhibitor of Raf and several growth factor receptors, is under investigation in combination with dacarbazine, a commonly used chemotherapeutic agent for the treatment of many cancers. The current phase I study investigates the effects of sorafenib on the...

  • Prospective Trial of a Novel Nomogram to Achieve Updated Vancomycin Trough Concentrations. Wesner, Amber R.; Brackbill, Marcia L.; Coyle, Larissa L.; Kidd, Robert S. // Interdisciplinary Perspectives on Infectious Diseases;2013, p1 

    Purpose. To determine if the use of a novel vancomycin nomogram predicts dosing regimens that achieve target trough concentrations equal to ormore accurate than dosing regimens calculated using traditional pharmacokinetic calculations, evaluate the incidence of subtherapeutic and...

  • Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics–Based Analysis of Adult Patients With Invasive Fungal Infections. Pascual, Andres; Csajka, Chantal; Buclin, Thierry; Bolay, Saskia; Bille, Jacques; Calandra, Thierry; Marchetti, Oscar // Clinical Infectious Diseases;Aug2012, Vol. 55 Issue 3, p381 

    This population-pharmacokinetics analysis involving adult patients with invasive fungal infections challenges recommended voriconazole dosing regimens. Higher oral than intravenous doses, followed by individualized adjustments based on therapeutic drug monitoring, are needed to improve...

  • Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. Uemura, Osamu; Hattori, Motoshi; Hataya, Hiroshi; Ito, Shuichi; Ito, Naoko; Akizawa, Tadao // Clinical & Experimental Nephrology;Dec2014, Vol. 18 Issue 6, p932 

    Background: Darbepoetin alfa (DA) is beneficial for pediatric patients for its less injection frequency and greater maximum dose compared to recombinant human erythropoietin. Here, we evaluated pharmacokinetics of DA in Japanese pediatric patients with chronic kidney disease (CKD). Methods: CKD...

  • Pharmacokinetics of vancomycin and dosing recommendations for trauma patients. Medellín-Garibay, Susanna E.; Ortiz-Martín, Belén; Rueda-Naharro, Aída; García, Benito; Romano-Moreno, Silvia; Barcia, Emilia // Journal of Antimicrobial Chemotherapy (JAC);Feb2016, Vol. 71 Issue 2, p471 

    Objectives: The objectives of this study were to characterize the population pharmacokinetics of vancomycin in trauma patients and to propose dosing schemes to optimize therapy. Patients and methods: Trauma patients from Hospital Universitario Severo Ochoa (Spain) receiving intravenous...

  • Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Tehraninejad, Ensieh; Hafezi, Maryam; Arabipoor, Arezoo; Aziminekoo, Elham; Chehrazi, Mohammad; Bahmanabadi, Akram // Journal of Assisted Reproduction & Genetics;Mar2012, Vol. 29 Issue 3, p259 

    Purpose: To compare the efficacy of cabergoline (Cb2) and intravenous human albumin (HA) in the prevention of ovarian hyperstimulation syndrome. Methods: In this randomized controlled trial study, 138 women who were at high risk for developing OHSS were randomly allocated into two groups. In...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics